Clinical Study Of New Type Enrofloxacin Injection Liquid

Avian colibacillosis is an infection disease of avian caused by Escherichia coli, which is considered as one of the principle cause of morbidity and mortality in poultry pathogens. In the process of clinical disease, it is associated with heavy economic losses to the poultry industry with a variety of diseases. Nither as main pathogens or secondary infection pathogens, it can cause significant economic losses in the poultry industry. Escherichia coli causes a variety of disease, including the yolk sac infection, respiratory tract infection, swollen head syndrome, septicemia and polyserositis, which caused the death of the most typical feature is the acute or subacute septicemia, air sacculitis, parahepatitis. Because the gene type variable of Escherichia coli, there is no effective vaccine to control the occurrence of this disease. At present, the treatment of colibacillosis mainlyrely on drug control, but many data showed that Escherichia coli were often resistant to antimaicrobials, including cefradine, tetracycline, chloramphenicol, sulfonamides, aminoglycosides and beta-lactam antibiotics. In order to reduce unnecessary economic losses, must be based on clinical experimental guidance before using the drug, the choice of highly sensitive drugs and best dose are the key to the treatment of this diseas.Enrofloxacin is a synthetic bactericidal agent in fluoroquinolone drugs specifically for animal use. The main characteristic of this antimicrobial agent are low toxicity, high bioavailability, excellent tissue penetration and long serum half-life. It is highly efficacious against of Gram-negative bacteria and some Gram-positive bacteria, even can inhibit some rickettsial and mycoplasma infection. Compared with the same kind of anti microbial agents, only a lower dose can achieve the desired therapeutic effect.This study analysised the clinical effect of new type of enrofloxacin injection through animal experiments. In the first, the concentration of bacillus infection of pathogenic Escherichiacoli were optimized, successfully established the artificial infection model of Escherichia coli and determined the best infection artificial infection dose was 1×107CFU/m L. Followed by the Escherichia coli infection model, we analysised different doses of enrofloxacin injection and determined the optimal dosing concentration was 1.75mg/kg. Subsequently, the clinical symptoms and blood biochemical indexes of the animal were detected and the safety of enrofloxacin injection were determined.It is proved that under this dose(1.75mg/kg), the better the body of drug absorption and the lowest on metabolism, toxicity and side effects. Finally, we detected new enrofloxacin injection on artificial infection and natural infection of chicken Escherichia coli disease treatment through animal experiments, the results showed that in low dose or high dose conditions of enrofloxacin injection, can not effectively cure chicken colibacillosis, only in the medium dose conditions in order to achieve the best therapeutic effect. We also found that administration treatmen before the Escherichia coli disease or epidemic situation, helps to control the occurrence of this disease, can achieve a better effect of prevention and treatment of diseases. According to the above results, this study can provide theoretical reference and guidance for clinical medicine.